ERAS
Erasca, Inc. $14.74 +1.10% 2026-10-02 종가 기준핵심 지표
yfinance 기준분기 실적
매출·순이익 · yfinance연간 실적 5년
SEC 10-K · 회계연도 · 달러잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
EPS 서프라이즈
최근 4분기 · 실제 vs 예상수익성·성장
최근 12개월 기준사업 개요
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorp